Erik K. Flemington

9.9k total citations · 1 hit paper
157 papers, 8.0k citations indexed

About

Erik K. Flemington is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Erik K. Flemington has authored 157 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 78 papers in Molecular Biology and 60 papers in Cancer Research. Recurrent topics in Erik K. Flemington's work include Viral-associated cancers and disorders (70 papers), Cancer-related molecular mechanisms research (36 papers) and Cytomegalovirus and herpesvirus research (22 papers). Erik K. Flemington is often cited by papers focused on Viral-associated cancers and disorders (70 papers), Cancer-related molecular mechanisms research (36 papers) and Cytomegalovirus and herpesvirus research (22 papers). Erik K. Flemington collaborates with scholars based in United States, China and France. Erik K. Flemington's co-authors include Samuel H. Speck, Zhen Lin, Qinyan Yin, Claire Fewell, Corinne Cayrol, Miguel R. Campanero, Melody Baddoo, Jane McBride, Jennifer Cameron and Prescott L. Deininger and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Erik K. Flemington

152 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties

1992 777 citations Erik K. Flemington et al. profile →

Peers

Countries citing papers authored by Erik K. Flemington

Since Specialization

Citations

This map shows the geographic impact of Erik K. Flemington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik K. Flemington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik K. Flemington more than expected).

Fields of papers citing papers by Erik K. Flemington

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik K. Flemington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik K. Flemington. The network helps show where Erik K. Flemington may publish in the future.

Co-authorship network of co-authors of Erik K. Flemington

This figure shows the co-authorship network connecting the top 25 collaborators of Erik K. Flemington. A scholar is included among the top collaborators of Erik K. Flemington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik K. Flemington. Erik K. Flemington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Human endogenous retroviruses (HERVs) associated with glioblastoma risk and prognosis 2025 ·Cancer Gene Therapy ·(unknown), Hui‐Yi Lin, Melody Baddoo, (unknown), (unknown), Chindo Hicks, David Adeiza Otohinoyi, Francesca Peruzzi, Zbigniew Madeja, Victoria P. Belancio, Erik K. Flemington, Krzysztof Reiss, Monika Rak	0
2	Comprehensive resolution and classification of the Epstein Barr virus transcriptome 2025 ·Nature Communications ·(unknown), Jia Wang, (unknown), (unknown), Tina O’Grady, (unknown), (unknown), Trang T. Nguyen, Melody Baddoo, Dorota Wyczechowska, Maria E. Morales, Yan Dong, Erik K. Flemington	0
3	Viral reprogramming of host transcription initiation 2024 ·Nucleic Acids Research ·Nathan Ungerleider, (unknown), Tina O’Grady, Trang Nguyen, Melody Baddoo, (unknown), (unknown), Monica Concha, (unknown), (unknown), (unknown), (unknown), (unknown), Dorota Wyczechowska, Maria E. Morales, Tianfang Ma, Yan Dong, Erik K. Flemington	3
4	Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor 2022 ·Oncogenesis ·(unknown), Hongjun Kang, (unknown), (unknown), Nathan Ungerleider, (unknown), (unknown), Lee Spraggon, Romel Somwar, Krzysztof Moroz, David H. Drewry, Matthew E. Burow, Erik K. Flemington, Marc Ladanyi, Sean Bong Lee	13
5	EBV miRNAs are potent effectors of tumor cell transcriptome remodeling in promoting immune escape 2021 ·PLoS Pathogens ·Nathan Ungerleider, (unknown), (unknown), Xia Wang, (unknown), Rolf Renne, Scott A. Tibbetts, Erik K. Flemington	26
6	Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy 2021 ·Cancer Letters ·Tianfang Ma, Shanshan Bai, Yanfeng Qi, Zhan Yang, Nathan Ungerleider, (unknown), Taavi K. Neklesa, Eva Corey, Scott M. Dehm, Kun Zhang, Erik K. Flemington, Yan Dong	16
7	High-Throughput Sequence Analysis of Peripheral T-Cell Lymphomas Indicates Subtype-Specific Viral Gene Expression Patterns and Immune Cell Microenvironments 2019 ·mSphere ·(unknown), Zhen Lin, Xia Wang, (unknown), Yan Dong, Erik K. Flemington	14
8	The Epstein Barr virus circRNAome 2018 ·PLoS Pathogens ·Nathan Ungerleider, Monica Concha, Zhen Lin, (unknown), Xia Wang, Subing Cao, Melody Baddoo, Walter N. Moss, Yi Yu, Michael Seddon, (unknown), Scott A. Tibbetts, Rolf Renne, Yan Dong, Erik K. Flemington	112
9	MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia 2017 ·Cancer Research ·Nakhle S. Saba, Deanna H. Wong, (unknown), (unknown), Patricia Lobelle‐Rich, Eman L. Dadashian, Delong Liu, Lorena Fontán, Erik K. Flemington, Cydney Nichols, Chingiz Underbayev, Hana Safah, Ari Melnick, Adrian Wiestner, Sarah E. M. Herman	40
10	A computational framework for distinguishing directversusindirect interactions in human functional protein–protein interaction networks 2017 ·Integrative Biology ·Suyu Mei, Erik K. Flemington, Kun Zhang	5
11	Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance 2016 ·Molecular Cancer Research ·Zhan Yang, Guanyi Zhang, Xiaojie Wang, Yanfeng Qi, Shanshan Bai, Dongying Li, Tianfang Ma, Oliver Sartor, Erik K. Flemington, Haitao Zhang, Peng Lee, Yan Dong	55
12	SON and Its Alternatively Spliced Isoforms Control MLL Complex-Mediated H3K4me3 and Transcription of Leukemia-Associated Genes 2016 ·Molecular Cell ·Jung‐Hyun Kim, Melody Baddoo, Eun Young Park, Joshua K. Stone, Hyeon‐Soo Park, Thomas W. Butler, Gang Huang, Xiaomei Yan, Florencia Pauli, R Myers, Ming Tan, Erik K. Flemington, Ssang‐Taek Lim, E. Ahn	34
13	Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a , in EBV-Positive Gastric Carcinomas 2015 ·Journal of Virology ·Michael J. Strong, Thomas Laskow, (unknown), Eugene Blanchard, Yaozhong Liu, Xia Wang, Melody Baddoo, Zhen Lin, Qinyan Yin, Erik K. Flemington	28
14	Elevated expression of long intergenic non‐coding RNA HOTAIR in a basal‐like variant of MCF‐7 breast cancer cells 2014 ·Molecular Carcinogenesis ·Yan Zhuang, Hong T. Nguyen, Matthew E. Burow, Ying Zhuo, Samir S. El‐Dahr, Yao Xiao, Subing Cao, Erik K. Flemington, Kenneth P. Nephew, Fang Fang, Bridgette M. Collins‐Burow, Lyndsay V. Rhodes, Qiang Yu, Janarthanan Jayawickramarajah, Bin Shan	33
15	Global Bidirectional Transcription of the Epstein-Barr Virus Genome during Reactivation 2013 ·Journal of Virology ·Tina O’Grady, Subing Cao, Michael J. Strong, Monica Concha, Xia Wang, Sandra Splinter BonDurant, Marie Adams, Melody Baddoo, (unknown), Zhen Lin, Claire Fewell, Qinyan Yin, Erik K. Flemington	47
16	Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-Associated Primary Effusion Lymphoma 2013 ·Molecular Cancer Therapeutics ·Zhiqiang Qin, Lu Dai, Jimena Trillo-Tinoco, Can E. Senkal, Wenxue Wang, (unknown), (unknown), Luis Del Valle, Paulo C. Rodrı́guez, Erik K. Flemington, Christina Voelkel‐Johnson, Charles D. Smith, Besim Öğretmen, Chris Parsons	54
17	Differences in Gastric Carcinoma Microenvironment Stratify According to EBV Infection Intensity: Implications for Possible Immune Adjuvant Therapy 2013 ·PLoS Pathogens ·Michael J. Strong, Guorong Xu, Joseph Coco, Carl Baribault, Dass S. Vinay, Michelle Lacey, Amy L. Strong, Teresa A. Lehman, Michael Seddon, Zhen Lin, Monica Concha, Melody Baddoo, MaryBeth Ferris, Kenneth F. Swan, Deborah E. Sullivan, Matthew E. Burow, Christopher M. Taylor, Erik K. Flemington	128
18	E2F1 Expression Is Deregulated and Plays an Oncogenic Role in Sporadic Burkitt's Lymphoma 2009 ·Cancer Research ·(unknown), (unknown), (unknown), Daniel Martín-Pérez, María-Jesús Artiga, Javier Menárguez, Erik K. Flemington, Miguel Á. Piris, Miguel R. Campanero	35
19	The Epstein–Barr virus transactivator Zta binds to its own promoter and is required for full promoter activity during anti-Ig- and TGF-beta1-mediated reactivation 2004 ·Virology ·Qinyan Yin, (unknown), Erik K. Flemington	14
20	Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway 2003 ·Proceedings of the National Academy of Sciences ·Hoon Ryu, Jung-Hee Lee, Beatrix A. Olofsson, (unknown), (unknown), (unknown), Erik K. Flemington, Jane Azizkhan‐Clifford, Robert J. Ferrante, Rajiv R. Ratan	225

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact